Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer
- PMID: 31492993
- DOI: 10.1007/s00259-019-04505-2
Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer
Abstract
Objective: The objective of this study was to develop a clinical nomogram to predict gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA-11-PET/CT) positivity in different clinical settings of PSA failure.
Materials and methods: Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled. Patients were stratified according to different clinical settings (first-time biochemical recurrence [BCR]: group 1; BCR after salvage therapy: group 2; biochemical persistence after radical prostatectomy [BCP]: group 3; advanced-stage PCa before second-line systemic therapies: group 4). First, we assessed 68Ga-PSMA-11-PET/CT positivity rate. Second, multivariable logistic regression analyses were used to determine predictors of positive scan. Third, regression-based coefficients were used to develop a nomogram predicting positive 68Ga-PSMA-11-PET/CT result and 200 bootstrap resamples were used for internal validation. Fourth, receiver operating characteristic (ROC) analysis was used to identify the most informative nomogram's derived cutoff. Decision curve analysis (DCA) was implemented to quantify nomogram's clinical benefit.
Results: 68Ga-PSMA-11-PET/CT overall positivity rate was 51.2%, while it was 40.3% in group 1, 54% in group 2, 60.5% in group 3, and 86.9% in group 4 (p < 0.001). At multivariable analyses, ISUP grade, PSA, PSA doubling time, and clinical setting were independent predictors of a positive scan (all p ≤ 0.04). A nomogram based on covariates included in the multivariate model demonstrated a bootstrap-corrected accuracy of 82%. The nomogram-derived best cutoff value was 40%. In DCA, the nomogram revealed clinical net benefit of > 10%.
Conclusions: This novel nomogram proved its good accuracy in predicting a positive scan, with values ≥ 40% providing the most informative cutoff in counselling patients to 68Ga-PSMA-11-PET/CT. This tool might be important as a guide to clinicians in the best use of PSMA-based PET imaging.
Keywords: Biochemical persistence; Biochemical recurrence; Nomogram; PSMA PET; Prediction; Prostate cancer.
Similar articles
-
Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng/ml external validation on a single institution database.Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2100-2105. doi: 10.1007/s00259-020-04696-z. Epub 2020 Jan 31. Eur J Nucl Med Mol Imaging. 2020. PMID: 32006061
-
Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.Eur Urol Oncol. 2023 Feb;6(1):41-48. doi: 10.1016/j.euo.2021.12.002. Epub 2021 Dec 20. Eur Urol Oncol. 2023. PMID: 34933814
-
Development and validation of a nomogram for predicting the likelihood of metastasis in prostate cancer patients undergoing Ga-68 PSMA PET/CT due to biochemical recurrence.Nucl Med Commun. 2022 Aug 1;43(8):952-958. doi: 10.1097/MNM.0000000000001591. Epub 2022 Jun 7. Nucl Med Commun. 2022. PMID: 35661662
-
68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15. Eur Urol Focus. 2018. PMID: 28753806
-
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14. Eur Urol. 2020. PMID: 30773328
Cited by
-
The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.Cancers (Basel). 2022 Dec 30;15(1):247. doi: 10.3390/cancers15010247. Cancers (Basel). 2022. PMID: 36612242 Free PMC article.
-
Challenges in the Use of Artificial Intelligence for Prostate Cancer Diagnosis from Multiparametric Imaging Data.Cancers (Basel). 2021 Aug 5;13(16):3944. doi: 10.3390/cancers13163944. Cancers (Basel). 2021. PMID: 34439099 Free PMC article.
-
Prediction nomogram based on 18F-FDG PET/CT and clinical parameters for patients with diffuse large B-cell lymphoma.Ann Hematol. 2023 Nov;102(11):3115-3124. doi: 10.1007/s00277-023-05336-w. Epub 2023 Jul 3. Ann Hematol. 2023. PMID: 37400729
-
Predictors of Bone Metastases at 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence.Diagnostics (Basel). 2022 May 24;12(6):1309. doi: 10.3390/diagnostics12061309. Diagnostics (Basel). 2022. PMID: 35741119 Free PMC article.
-
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.Cancers (Basel). 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027. Cancers (Basel). 2023. PMID: 37046687 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous